

<u>DB Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
USPT,JPAB,EPAB,DWPI,TDBD	L10 and (autoimmune disease)	13	<a href="#"><u>L11</u></a>
USPT,JPAB,EPAB,DWPI,TDBD	(ds oligonucleotide)	130	<a href="#"><u>L10</u></a>
USPT,JPAB,EPAB,DWPI,TDBD	Rice-john-m\$.in.	7	<a href="#"><u>L9</u></a>
USPT,JPAB,EPAB,DWPI,TDBD	Kohn-leonard-d\$.in.	3	<a href="#"><u>L8</u></a>
USPT,JPAB,EPAB,DWPI,TDBD	L5 and (ds polynucleotide)	0	<a href="#"><u>L7</u></a>
USPT,JPAB,EPAB,DWPI,TDBD	L5 and (MHC)	25	<a href="#"><u>L6</u></a>
USPT,JPAB,EPAB,DWPI,TDBD	L1 and (autoimmune disease)	111	<a href="#"><u>L5</u></a>
USPT,JPAB,EPAB,DWPI,TDBD	L1 and ((MHC gene) or (TAP-1 or TAP-2) or PKR or JAK or STAT)	33	<a href="#"><u>L4</u></a>
USPT,JPAB,EPAB,DWPI,TDBD	L1 and (immune recognition)	8	<a href="#"><u>L3</u></a>
USPT,JPAB,EPAB,DWPI,TDBD	L1 and ((MHC gene) adj expression)	2	<a href="#"><u>L2</u></a>
USPT,JPAB,EPAB,DWPI,TDBD	(ds RNA) or (ds DNA)	1415	<a href="#"><u>L1</u></a>

S16 5 S1 AND (ANTIGEN (W) PRESENTATION)  
 S17 3 RD (unique items)  
 S18 0 S1 AND (NON (W) SPECIFIC (W) SEQUENCE)  
 S19 355 S1 AND (VACCINE OR TREATMENT OR IMMUNOTHERAPY)  
 S20 203 RD (unique items)  
 S21 0 S20 AND (ENHANCED (W) IMMUNE (W) RESPONSE)  
 S22 4 S20 AND (REVIEW)  
 S23 0 AU=(KOHN, L?) OR (KOHN L?)  
 S24 0 AU=(KOHN, LEONARD) OR (KOHN LEONARD)  
 S25 3 AU=(SUZUKI, K?) OR (SUZUKI K?)  
 S26 3 RD (unique items)

?s s25 and s20

3 S25

203 S20

S27 0 S25 AND S20

?ds

Set	Items	Description
S1	2608	(DS (W) (RNA OR DNA OR OLIGONUCLEOTIDE OR POLYNUCLEOTIDE OR PLASMID))
S2	3	S1 AND (MHC (W) GENE)
S3	1	RD (unique items)
S4	120	S1 AND (TAP-1 OR TAP-2 OR PKR OR IFNBETA OR MAP OR JAK OR - STAT)
S5	0	S4 AND (ANTIGEN (W) PRESENTATION)
S6	0	S4 AND (ANTIGEN (W) PRESENTATION)
S7	0	S4 AND (AUTOIMMUNE (W) DISEASE)
S8	0	S4 AND (AUTOIMMUNE)
S9	0	S4 AND (IMMUNE (W) RECOGNITION)
S10	0	S4 AND ((ABERRANT OR ENHANCED) (W) (EXPRESSION))
S11	0	S4 AND (THYROID OR THYROCYTE)
S12	4	S1 AND (ANTIGEN (W) PRESENTING (W) CELL?)
S13	2	RD (unique items)
S14	8	S1 AND (AUTOIMMUNE (W) RESPONSE)
S15	5	RD (unique items)
S16	5	S1 AND (ANTIGEN (W) PRESENTATION)
S17	3	RD (unique items)
S18	0	S1 AND (NON (W) SPECIFIC (W) SEQUENCE)
S19	355	S1 AND (VACCINE OR TREATMENT OR IMMUNOTHERAPY)
S20	203	RD (unique items)
S21	0	S20 AND (ENHANCED (W) IMMUNE (W) RESPONSE)
S22	4	S20 AND (REVIEW)
S23	0	AU=(KOHN, L?) OR (KOHN L?)
S24	0	AU=(KOHN, LEONARD) OR (KOHN LEONARD)
S25	3	AU=(SUZUKI, K?) OR (SUZUKI K?)
S26	3	RD (unique items)
S27	0	S25 AND S20

?logoff

13jan01 15:16:08 User259876 Session D178.2

\$6.09 1.904 DialUnits File155

\$2.20 11 Type(s) in Format 3

\$2.20 11 Types

\$8.29 Estimated cost File155

\$11.70 2.089 DialUnits File5

\$4.95 3 Type(s) in Format 3

\$4.95 3 Types

\$16.65 Estimated cost File5

\$18.04 2.123 DialUnits File73

\$9.40 4 Type(s) in Format 3

\$9.40 4 Types

\$27.44 Estimated cost File73

OneSearch, 3 files, 6.116 DialUnits FileOS

\$1.75 TYMNET

\$54.13 Estimated cost this search

\$54.55 Estimated total session cost 6.231 DialUnits

### Status: Path 1 of [Dialog Information Services via Modem]

### Status: Initializing TCP/IP using (UseTelnetProto 1 ServiceID pto-dialog)  
Trying 3106900061...Open

DIALOG INFORMATION SERVICES

PLEASE LOGON:

\*\*\*\*\* HHHHHHHH SSSSSSSS?

### Status: Signing onto Dialog

\*\*\*\*\*

ENTER PASSWORD:

\*\*\*\*\* HHHHHHHH SSSSSSSS? \*\*\*\*\*

Welcome to DIALOG

### Status: Connected

Dialog level 00.12.12D

Last logoff: 07jan01 10:59:11

Logon file001 13jan01 14:41:20

\*\*\* ANNOUNCEMENT \*\*\*

\*\*\*

NEW FILE RELEASED

\*\*\*Daily and Sunday Telegraph (London) Papers (File 756)

\*\*\*The Mirror Group Publications (United Kingdom) (File 757)

\*\*\*Prous Science Daily Essentials (Files 458, 459)

\*\*\*WIPO/PCT Patents Fulltext (File 349)

UPDATING RESUMED

\*\*\*Extel News Cards from Primark (File 501)

\*\*\*TFSD Ownership Database (File 540)

\*\*\*

RELOADED

\*\*\*Kompass Central/Eastern Europe (File 593)

\*\*\*Kompass Latin America (File 586)

\*\*\*Brands and their Companies (File 116)

\*\*\*Kompass USA (File 584)

\*\*\*Kompass Canada (File 594)

\*\*\*PsyncINFO (File 11)

FILES REMOVED

\*\*\*EconBase (File 565)

\*\*\*Unlisted Drugs (File 140)

>>>Get immediate news with Dialog's First Release  
news service. First Release updates major newswire  
databases within 15 minutes of transmission over the  
wire. First Release provides full Dialog searchability  
and full-text features. To search First Release files in  
OneSearch simply BEGIN FIRST for coverage from Dialog's  
broad spectrum of news wires.

>>> Enter BEGIN HOMEBASE for Dialog Announcements <<<

>>> of new databases, price changes, etc. <<<

\*\*\*\*

KWIC is set to 50.

HIGHLIGHT set on as '\*'

\*\*\* NEW Current Year Ranges Install \*\*\*

File 1:ERIC 1966-2000/Dec 05

(c) format only 2000 The Dialog Corporation

Set Items Description

--- ----

?b 155, 5, 73

13jan01 14:41:38 User259876 Session D178.1

\$0.40 0.115 DialUnits File1  
\$0.40 Estimated cost File1  
\$0.02 TYMNET  
\$0.42 Estimated cost this search  
\$0.42 Estimated total session cost 0.115 DialUnits

SYSTEM:OS - DIALOG OneSearch

File 155:MEDLINE(R) 1966-2000/Dec W4

(c) format only 2000 Dialog Corporation

**\*File 155: For information on updating, changes to the file, and check tags information please see Help News155.**

File 5:Biosis Previews(R) 1969-2001/Jan W2

(c) 2001 BIOSIS

File 73:EMBASE 1974-2001/Jan W2

(c) 2001 Elsevier Science B.V.

**\*File 73: For details about update codes see Help News73.**

Set	Items	Description
-----	-------	-------------

Set	Items	Description
-----	-------	-------------

?s (ds (w) (RNA or DNA or oligonucleotide or polynucleotide or plasmid))

18368 DS

829702 RNA

1563264 DNA

72584 OLIGONUCLEOTIDE

8939 POLYNUCLEOTIDE

151224 PLASMID

S1 2608 (DS (W) (RNA OR DNA OR OLIGONUCLEOTIDE OR POLYNUCLEOTIDE OR PLASMID))

?s s1 and (MHC (w) gene)

2608 S1

75721 MHC

1554207 GENE

1913 MHC(W) GENE

S2 3 S1 AND (MHC (W) GENE)

?rd

...completed examining records

S3 1 RD (unique items)

?t s3/3,k/all

3/3,K/1 (Item 1 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2000 Dialog Corporation. All rts. reserv.

09849984 99162596

**Activation of target-tissue immune-recognition molecules by double-stranded polynucleotides.**

Suzuki K; Mori A; Ishii KJ; Saito J; Singer DS; Klinman DM; Krause PR; Kohn LD

Cell Regulation Section, Metabolic Diseases-Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA.

Proceedings of the National Academy of Sciences of the United States of America (UNITED STATES) Mar 2 1999, 96 (5) p2285-90, ISSN 0027-8424

Journal Code: PV3

Languages: ENGLISH

Document type: JOURNAL ARTICLE

... Autoimmune responses can be triggered by viral infections or tissue injuries. We show that the ability of a virus or a tissue injury to increase \*MHC\* \*gene\* expression is duplicated by any fragment of double-stranded (\*ds\*) \*DNA\* or dsRNA introduced into the cytoplasm of nonimmune cells. Activation is sequence-independent, is induced by ds polynucleotides as small as 25 bp in length...

?ds

Set	Items	Description
S1	2608	(DS (W) (RNA OR DNA OR OLIGONUCLEOTIDE OR POLYNUCLEOTIDE OR PLASMID))
S2	3	S1 AND (MHC (W) GENE)
S3	1	RD (unique items)
?s s1 and		(TAP-1 or TAP-2 or PKR or IFNBeta or MAP or JAK or STAT)
	2608	S1
	22	TAP-1
	12	TAP-2
	1225	PKR
	407	IFNBETA
	129733	MAP
	3405	JAK
	11919	STAT
S4	120	S1 AND (TAP-1 OR TAP-2 OR PKR OR IFNBETA OR MAP OR JAK OR STAT)
?s s4 and		(anitgen (w) presentation)
	120	S4
	42	ANITGEN
	192579	PRESENTATION
	2	ANITGEN(W)PRESENTATION
S5	0	S4 AND (ANITGEN (W) PRESENTATION)
?s s4 and		(antigen (w) presentation)
	120	S4
	839168	ANTIGEN
	192579	PRESENTATION
	19481	ANTIGEN(W)PRESENTATION
S6	0	S4 AND (ANTIGEN (W) PRESENTATION)
?s s4 and		(autoimmune (w) disease)
	120	S4
	129000	AUTOIMMUNE
	3803231	DISEASE
	32624	AUTOIMMUNE(W)DISEASE
S7	0	S4 AND (AUTOIMMUNE (W) DISEASE)
?s s4 and		(autoimmune)
	120	S4
	129000	AUTOIMMUNE
S8	0	S4 AND (AUTOIMMUNE)
?s s4 and		(immune (w) recognition)
	120	S4
	948169	IMMUNE
	251732	RECOGNITION
	2295	IMMUNE(W)RECOGNITION
S9	0	S4 AND (IMMUNE (W) RECOGNITION)
?s s4 and		((aberrant or enhanced) (w) (expression))
	120	S4
	41003	ABERRANT
	535608	ENHANCED
	1338049	EXPRESSION
	11074	(ABERRANT OR ENHANCED) (W)EXPRESSION
S10	0	S4 AND ((ABERRANT OR ENHANCED) (W) (EXPRESSION))
?s s4 and		(thyroid or thyrocyte)
	120	S4
	234361	THYROID
	862	THYROCYTE
S11	0	S4 AND (THYROID OR THYROCYTE)
?ds		

Set	Items	Description
S1	2608	(DS (W) (RNA OR DNA OR OLIGONUCLEOTIDE OR POLYNUCLEOTIDE OR PLASMID))
S2	3	S1 AND (MHC (W) GENE)
S3	1	RD (unique items)
S4	120	S1 AND (TAP-1 OR TAP-2 OR PKR OR IFNBETA OR MAP OR JAK OR STAT)
S5	0	S4 AND (ANITGEN (W) PRESENTATION)

S6 0 S4 AND (ANTIGEN (W) PRESENTATION)  
 S7 0 S4 AND (AUTOIMMUNE (W) DISEASE)  
 S8 0 S4 AND (AUTOIMMUNE)  
 S9 0 S4 AND (IMMUNE (W) RECOGNITION)  
 S10 0 S4 AND ((ABERRANT OR ENHANCED) (W) (EXPRESSION))  
 S11 0 S4 AND (THYROID OR THYROCYTE)

?s s1 and (antigen (w) presenting (w) cell?)

Processing

Processing

2608 S1  
 839168 ANTIGEN  
 175387 PRESENTING  
 6743875 CELL?  
 25380 ANTIGEN(W)PRESENTING(W)CELL?  
 S12 4 S1 AND (ANTIGEN (W) PRESENTING (W) CELL?)

?rd

...completed examining records

S13 2 RD (unique items)

?t s13/3,k/all

13/3,K/1 (Item 1 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2000 Dialog Corporation. All rts. reserv.

09905346 99160629

**Maturation, activation, and protection of dendritic cells induced by double-stranded RNA.**

Cella M; Salio M; Sakakibara Y; Langen H; Julkunen I; Lanzavecchia A  
 Basel Institute for Immunology, CH-4005 Basel, Switzerland. cella@bii.ch  
 Journal of experimental medicine (UNITED STATES) Mar 1 1999, 189 (5)  
 p821-9, ISSN 0022-1007 Journal Code: I2V

Languages: ENGLISH

Document type: JOURNAL ARTICLE

... cytokines or for conserved patterns characteristic of infectious agents. Here we show that human DCs are activated by influenza virus infection and by double-stranded (\*ds\*)RNA\*. This activation results not only in increased antigen presentation and T cell stimulatory capacity, but also in resistance to the cytopathic effect of the virus, mediated by the production of type I interferon, and upregulation of MxA. Because dsRNA stimulates both maturation and resistance, DCs can serve as altruistic \*antigen\*-\*presenting\* \*cells\* capable of sustaining viral antigen production while acquiring the capacity to trigger naive T cells and drive polarized T helper cell type 1 responses.

13/3,K/2 (Item 2 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2000 Dialog Corporation. All rts. reserv.

05847563 89233254

**Lupus erythematosus cell formation by a monoclonal antibody derived from an autoimmune MRL/Mp-lpr/lpr mouse.**

Kanai Y; Yamauchi S; Hashiba-Kanai Y  
 Department of Molecular Oncology, University of Tokyo, Japan.  
 Immunology letters (NETHERLANDS) Jan 15 1989, 20 (1) p9-13, ISSN  
 0165-2478 Journal Code: GIH

Languages: ENGLISH

Document type: JOURNAL ARTICLE

... shown to cross-react with single-stranded (ss) DNA. Detailed examination revealed that MRP-2 MoAb bound to a conformational epitope formed between double-stranded (\*ds\*) DNA\* and total histone: both H3 and H4 were essential for the formation of this conformational epitope with dsDNA. Because of this characteristic of the MoAb...

; \*Antigen\*-\*Presenting\* \*Cells\*--Pathology--PA; Autoimmune Diseases

--Genetics--GE; Autoimmune Diseases--Pathology--PA; Deoxyribonucleoprotein  
s--Immunology--IM; DNA--Immunology--IM; DNA--Metabolism--ME; Epitopes  
--Immunology--IM; Histones--Metabolism--ME...  
?ds

Set	Items	Description
S1	2608	(DS (W) (RNA OR DNA OR OLIGONUCLEOTIDE OR POLYNUCLEOTIDE OR PLASMID))
S2	3	S1 AND (MHC (W) GENE)
S3	1	RD (unique items)
S4	120	S1 AND (TAP-1 OR TAP-2 OR PKR OR IFNBETA OR MAP OR JAK OR - STAT)
S5	0	S4 AND (ANITGEN (W) PRESENTATION)
S6	0	S4 AND (ANTIGEN (W) PRESENTATION)
S7	0	S4 AND (AUTOIMMUNE (W) DISEASE)
S8	0	S4 AND (AUTOIMMUNE)
S9	0	S4 AND (IMMUNE (W) RECOGNITION)
S10	0	S4 AND ((ABERRANT OR ENHANCED) (W) (EXPRESSION))
S11	0	S4 AND (THYROID OR THYROCYTE)
S12	4	S1 AND (ANTIGEN (W) PRESENTING (W) CELL?)
S13	2	RD (unique items)

?s s1 and (autoimmune (w) response)  
2608 S1  
129000 AUTOIMMUNE  
2214457 RESPONSE  
3762 AUTOIMMUNE(W)RESPONSE  
S14 8 S1 AND (AUTOIMMUNE (W) RESPONSE)  
?rd  
...completed examining records  
S15 5 RD (unique items)  
?t s15/3,k/all

15/3,K/1 (Item 1 from file: 155)  
DIALOG(R)File 155:MEDLINE(R)  
(c) format only 2000 Dialog Corporation. All rts. reserv.

09485917 98207352

[Immunology in medical practice. III. Disseminated lupus erythematosus:  
disturbed apoptosis?]

Immunologie in de medische praktijk. III Lupus erythematosus  
disseminatus: gestoorde apoptose?

Berden JH

Academisch Ziekenhuis, afd. Nierziekten, Nijmegen.

Nederlands tijdschrift voor geneeskunde (NETHERLANDS) Sep 27 1997, 141  
(39) p1848-54, ISSN 0028-2162 Journal Code: NUK

Languages: DUTCH Summary Languages: ENGLISH

Document type: JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL ; English  
Abstract

The main feature of systemic lupus erythematosus (SLE) is formation of  
antinuclear antibodies, particularly against double-stranded (\*ds\*) \*DNA\*.  
This \*autoimmune\* \*response\* is T cell- and (auto)antigen-dependent, but  
dsDNA is very poorly immunogenic. Recent data suggest that the nucleosome  
is the principal autoantigen in SLE...

15/3,K/2 (Item 2 from file: 155)  
DIALOG(R)File 155:MEDLINE(R)  
(c) format only 2000 Dialog Corporation. All rts. reserv.

09101535 97187533

Revisiting autoantibody profiles in systemic lupus erythematosus.

Olhoffer IH; Peng SL; Craft J

Section of Rheumatology, Yale University School of Medicine, New Haven,  
CT, USA.

Journal of rheumatology (CANADA) Feb 1997, 24 (2) p297-302, ISSN

0315-162X Journal Code: JWX  
Contract/Grant No.: AR40072, AR, NIAMS; AR42475, AR, NIAMS  
Languages: ENGLISH  
Document type: JOURNAL ARTICLE

... To obtain more definitive assays of the spectrum of soluble autoantigens targeted by individual patients with systemic lupus erythematosus (SLE) and to determine whether the \*autoimmune\* \*response\* is restricted in specificity. Although there are many reports of a broad spectrum of autoantibody specificities in SLE, none has considered the diversity of autoantibody sets, which may more accurately describe the \*autoimmune\* \*response\*. METHODS: Sera of 68 patients with SLE were assayed for autoantibodies by ELISA and/or immunoprecipitation. Specificities were grouped into sets, including double stranded (\*ds\*) \*DNA\* and/or histone, U1 RNP and/or Sm, Ro and/or La, ribosomes, Ku, Ki, and others. An analysis was also performed of reported SLE...

15/3,K/3 (Item 3 from file: 155)  
DIALOG(R)File 155:MEDLINE(R)  
(c) format only 2000 Dialog Corporation. All rts. reserv.

08694948 95347760

**Induction of autoantibodies in normal mice by injection of nucleobindin and natural occurrence of antibodies against nucleobindin in autoimmune MRL/lpr/lpr mice.**

Kanai Y; Takeda O; Miura K; Amagai M; Kaneko T; Kubota T; Kanai Y; Tanuma S; Kurosawa Y

Department of Molecular Oncology, University of Tokyo, Japan.

Immunology letters (NETHERLANDS) Feb 1995, 45 (1-2) p35-42, ISSN 0165-2478 Journal Code: GIH

Languages: ENGLISH

Document type: JOURNAL ARTICLE

Our previous works have shown that nucleobindin (Nuc) or recombinant (r) Nuc not only augments anti-DNA antibody production in vitro but also accelerates \*autoimmune\* \*response\* in vivo in MRL/+/+ (MRL/n) mice which are the substrain of autoimmune MRL/lpr/lpr (MRL/l) mice. To investigate whether rNuc can induce \*autoimmune\* \*response\* similarly in naive mice, we carried out intraperitoneal (i.p.) injection of rNuc (5 micrograms) without adjuvant into 8-week-old female BALB/c mice...

... the mice began to show IgG hypergammaglobulinemia (HG) followed by elevation of a number of autoantibodies of the IgG class such as anti-double-stranded (\*ds\*) \*DNA\*, anti-U1 ribonuclear protein (RNP), anti-ssB(La) and anti-Fc antibodies (RF), but not by anti-Sm antibodies. However, the IgG anti-dsDNA antibody...

15/3,K/4 (Item 1 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2001 Elsevier Science B.V. All rts. reserv.

07019305 EMBASE No: 1997308294

**Immunology in medical practice. III. Systemic lupus erythematosus: Disturbed apoptosis?**

IMMUNOLOGIE IN DE MEDISCHE PRAKTIJK. III. LUPUS ERYTHEMATODES  
DISSEMINATUS: GESTOORDE APOPTOSE?

Berden J.H.M.

Prof. Dr. J.H.M. Berden, Academisch Ziekenhuis, Afd. Nierziekten, Postbus 9101, 6500 HB Nijmegen Netherlands

Nederlands Tijdschrift voor Geneeskunde ( NED. TIJDSCHR. GENEESKD. ) ( Netherlands) 1997, 141/39 (1848-1854)

CODEN: NETJA ISSN: 0028-2162

DOCUMENT TYPE: Journal; Review

LANGUAGE: DUTCH SUMMARY LANGUAGE: ENGLISH; DUTCH



NUMBER OF REFERENCES: 67

The main feature of systemic lupus erythematosus (SLE) is formation of antinuclear antibodies, particularly against double-stranded (\*ds\*) \*DNA\*. This \*autoimmune\* \*response\* is T cell- and (auto)antigen-dependent, but dsDNA is very poorly immunogenic. Recent data suggest that the nucleosome is the principal autoantigen in SLE...

15/3,K/5 (Item 2 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2001 Elsevier Science B.V. All rts. reserv.

06068968 EMBASE No: 1995099434

**Induction of autoantibodies in normal mice by injection or nucleobinin and natural occurrence of antibodies against nucleobindin in autoimmune MRL/lpr/lpr mice**

Kanai Y.; Takeda O.; Miura K.; Amagai M.; Kaneko T.; Kubota T.; Kanai Y.; Tanuma S.-I.; Kurosawa Y.

Department of Molecular Oncology, Institute of Medical Science,  
University of Tokyo, Minato-Ku, Tokyo 108 Japan  
Immunology Letters ( IMMUNOL. LETT. ) (Netherlands) 1995, 45/1-2 (35-42)  
CODEN: IMLED ISSN: 0165-2478  
DOCUMENT TYPE: Journal; Article  
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

Our previous works have shown that nucleobindin (Nuc) or recombinant (r) Nuc not only augments anti-DNA antibody production in vitro but also accelerates \*autoimmune\* \*response\* in vivo in MRL/+/+(MRL/n): mice which are the substrain of autoimmune MRL/lpr/lpr (MRL/l) mice. To investigate whether rNuc can induce \*autoimmune\* \*response\* similarly in naive mice, we carried out intraperitoneal (i.p.) injection of rNuc (5 mug) without adjuvant into 8-week-old female BALB/c mice...  
...the mice began to show IgG hypergammaglobulinemia (HG) followed by elevation of a number of autoantibodies of the IgG class such as anti-double-stranded (\*ds\*) \*DNA\*, anti-U1 ribonuclear protein (RNP), anti-ssB(La) and anti-Fc antibodies (RF), but not by anti-Sm antibodies. However, the IgG anti-dsDNA antibody...  
?ds

Set	Items	Description
S1	2608	(DS (W) (RNA OR DNA OR OLIGONUCLEOTIDE OR POLYNUCLEOTIDE OR PLASMID))
S2	3	S1 AND (MHC (W) GENE)
S3	1	RD (unique items)
S4	120	S1 AND (TAP-1 OR TAP-2 OR PKR OR IFNBETA OR MAP OR JAK OR - STAT)
S5	0	S4 AND (ANTIGEN (W) PRESENTATION)
S6	0	S4 AND (ANTIGEN (W) PRESENTATION)
S7	0	S4 AND (AUTOIMMUNE (W) DISEASE)
S8	0	S4 AND (AUTOIMMUNE)
S9	0	S4 AND (IMMUNE (W) RECOGNITION)
S10	0	S4 AND ((ABERRANT OR ENHANCED) (W) (EXPRESSION))
S11	0	S4 AND (THYROID OR THYROCYTE)
S12	4	S1 AND (ANTIGEN (W) PRESENTING (W) CELL?)
S13	2	RD (unique items)
S14	8	S1 AND (AUTOIMMUNE (W) RESPONSE)
S15	5	RD (unique items)
?s s1 and (antigen (w) presentation)		
	2608	S1
	839168	ANTIGEN
	192579	PRESENTATION
	19481	ANTIGEN(W)PRESENTATION
S16	5	S1 AND (ANTIGEN (W) PRESENTATION)
?rd		
...completed examining records		

s17 3 RD (unique items)  
?t s17/3,k/all

17/3,K/1 (Item 1 from file: 155)  
DIALOG(R)File 155:MEDLINE(R)  
(c) format only 2000 Dialog Corporation. All rts. reserv.

09905346 99160629

**Maturation, activation, and protection of dendritic cells induced by double-stranded RNA.**

Cella M; Salio M; Sakakibara Y; Langen H; Julkunen I; Lanzavecchia A  
Basel Institute for Immunology, CH-4005 Basel, Switzerland. cella@bii.ch  
Journal of experimental medicine (UNITED STATES) Mar 1 1999, 189 (5)  
p821-9, ISSN 0022-1007 Journal Code: I2V  
Languages: ENGLISH  
Document type: JOURNAL ARTICLE

... cytokines or for conserved patterns characteristic of infectious agents. Here, we show that human DCs are activated by influenza virus infection and by double-stranded (\*ds\*)RNA\*. This activation results not only in increased \*antigen\* \*presentation\* and T cell stimulatory capacity, but also in resistance to the cytopathic effect of the virus, mediated by the production of type I interferon, and...

; \*Antigen\* \*Presentation\*; Autocrine Communication; Cytopathogenic Effect, Viral; Dendritic Cells--Virology--VI; Histocompatibility Antigens Class I--Immunology--IM; Interferon-alpha--Biosynthesis--BI; Lymphocyte Transformation; Major Histocompatibility Complex--Immunology...

17/3,K/2 (Item 1 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2001 BIOSIS. All rts. reserv.

12310809 BIOSIS NO.: 200000068676

**DNA and RNA-based vaccines: Principles, progress and prospects.**

AUTHOR: Leitner Wolfgang W; Ying Han; Restifo Nicholas P(a)  
AUTHOR ADDRESS: (a)National Cancer Institute, National Institutes of Health, Building 10, Bethesda, MD\*\*USA  
JOURNAL: Vaccine 18 (9-10):p765-777 Dec. 10, 1999  
ISSN: 0264-410X  
DOCUMENT TYPE: Literature Review  
RECORD TYPE: Abstract  
LANGUAGE: English  
SUMMARY LANGUAGE: English

...ABSTRACT: transfected with 'self-replicating' vectors briefly produce large amounts of antigen before undergoing apoptotic death. This death is a likely result of requisite double-stranded (\*ds\*) RNA\* intermediates, which also have been shown to super-activate DC. Thus, the enhanced immunogenicity of 'self-replicating' genetic vaccines may be a result of the...

MISCELLANEOUS TERMS: \*antigen\* \*presentation\*;

17/3,K/3 (Item 1 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2001 Elsevier Science B.V. All rts. reserv.

07615057 EMBASE No: 1999091629

**Activation of target-tissue immune-recognition molecules by double-stranded polynucleotides**

Suzuki K.; Mori A.; Ishii K.J.; Saito J.; Singer D.S.; Klinman D.M.; Krause P.R.; Kohn L.D.  
K. Suzuki, Division of Viral Products, Ctr. for Biologics/Evaluation Res., Food and Drug Administration, Bethesda, MD 20892 United States  
AUTHOR EMAIL: lenk@bdg10.niddk.nih.gov

Proceedings of the National Academy of Sciences of the United States of America ( PROC. NATL. ACAD. SCI. U. S. A. ) (United States) 02 MAR 1999  
 , 96/5 (2285-2290)  
 CODEN: PNAS A ISSN: 0027-8424  
 DOCUMENT TYPE: Journal; Article  
 LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH  
 NUMBER OF REFERENCES: 39

...We show that the ability of a virus or a tissue injury to increase MHC gene expression is duplicated by any fragment of double-stranded (\*ds\*) \*DNA\* or dsRNA introduced into the cytoplasm of nonimmune cells. Activation is sequence- independent, is induced by ds polynucleotides as small as 25 bp in length...

# MEDICAL DESCRIPTORS:

autoimmunity; gene expression; cell activation; single strand conformation polymorphism; \*antigen\* \*presentation\*; gene therapy; enzyme activity; major histocompatibility complex; cytoplasm; article; priority journal  
 ?ds

Set	Items	Description
S1	2608	(DS (W) (RNA OR DNA OR OLIGONUCLEOTIDE OR POLYNUCLEOTIDE OR PLASMID))
S2	3	S1 AND (MHC (W) GENE)
S3	1	RD (unique items)
S4	120	S1 AND (TAP-1 OR TAP-2 OR PKR OR IFNBETA OR MAP OR JAK OR - STAT)
S5	0	S4 AND (ANTIGEN (W) PRESENTATION)
S6	0	S4 AND (ANTIGEN (W) PRESENTATION)
S7	0	S4 AND (AUTOIMMUNE (W) DISEASE)
S8	0	S4 AND (AUTOIMMUNE)
S9	0	S4 AND (IMMUNE (W) RECOGNITION)
S10	0	S4 AND ((ABERRANT OR ENHANCED) (W) (EXPRESSION))
S11	0	S4 AND (THYROID OR THYROCYTE)
S12	4	S1 AND (ANTIGEN (W) PRESENTING (W) CELL?)
S13	2	RD (unique items)
S14	8	S1 AND (AUTOIMMUNE (W) RESPONSE)
S15	5	RD (unique items)
S16	5	S1 AND (ANTIGEN (W) PRESENTATION)
S17	3	RD (unique items)
?s s1 and (non (w) specific (w) sequence)		
	2608	S1
	3346603	NON
	1974186	SPECIFIC
	1129368	SEQUENCE
	22	NON(W) SPECIFIC (W) SEQUENCE
S18	0	S1 AND (NON (W) SPECIFIC (W) SEQUENCE)
?s s1 and (vaccine or treatment or immunotherapy)		
	2608	S1
	184950	VACCINE
	3375384	TREATMENT
	78707	IMMUNOTHERAPY
S19	355	S1 AND (VACCINE OR TREATMENT OR IMMUNOTHERAPY)
?rd		
...examined 50 records (50)		
...examined 50 records (100)		
...examined 50 records (150)		
...examined 50 records (200)		
...examined 50 records (250)		
...examined 50 records (300)		
...examined 50 records (350)		
...completed examining records		
S20	203	RD (unique items)
?s s20 and (enhanced (w) immune (w) response)		
	203	S20
	535608	ENHANCED
	948169	IMMUNE

2214457 RESPONSE  
241 ENHANCED(W) IMMUNE(W) RESPONSE  
S21 0 S20 AND (ENHANCED (W) IMMUNE (W) RESPONSE)  
?s s20 and (review)  
203 S20  
1091366 REVIEW  
S22 4 S20 AND (REVIEW)  
?t s22/3,k/all

22/3,K/1 (Item 1 from file: 155)  
DIALOG(R) File 155:MEDLINE(R)  
(c) format only 2000 Dialog Corporation. All rts. reserv.

08982127 97023541

**Transverse myelopathy in SLE: clinical features and functional outcomes.**  
Chan KF; Boey ML  
Department of Rehabilitation Medicine, Tan Tock Seng Hospital, Singapore.  
Lupus (ENGLAND) Aug 1996, 5 (4) p294-9, ISSN 0961-2033  
Journal Code: BRN  
Languages: ENGLISH  
Document type: JOURNAL ARTICLE; REVIEW; REVIEW, MULTICASE

... one of neurogenic bladder were reported early in the diagnosis of SLE (median of two years). Neurogenic bowel and bladder and presence of ANA and \*ds\*-DNA\* were invariable. Urodynamics assessment in six patients showed abnormal detrusor behavior in all. CT scans and myelograms were uninformative and CSF studies were normal. ESR and complement levels were insensitive as markers of disease activity. The \*treatment\* regimens included pulses of methylprednisolone and/or cyclophosphamide followed by prednisolone and high dose prednisolone from onset. The functional outcomes were uniformly good-with independent...

... range of three to 45 days) whilst only two were referred for inpatient rehabilitation. Bladder abnormalities persisted despite motor recovery and would require long-term \*review\*.

...; Methylprednisolone--Therapeutic Use--TU; Middle Age; Myelitis, Transverse--Drug Therapy--DT; Myelitis, Transverse--Rehabilitation--RH; Paraplegia--Etiology--ET; Prednisone--Therapeutic Use--TU; Quadriplegia --Etiology--ET; \*Treatment\* Outcome; Urodynamics

22/3,K/2 (Item 1 from file: 5)  
DIALOG(R) File 5:BIOSIS Previews(R)  
(c) 2001 BIOSIS. All rts. reserv.

12310809 BIOSIS NO.: 200000068676

**DNA and RNA-based vaccines: Principles, progress and prospects.**  
AUTHOR: Leitner Wolfgang W; Ying Han; Restifo Nicholas P(a)  
AUTHOR ADDRESS: (a)National Cancer Institute, National Institutes of Health, Building 10, Bethesda, MD\*\*USA  
JOURNAL: Vaccine 18 (9-10):p765-777 Dec. 10, 1999  
ISSN: 0264-410X  
DOCUMENT TYPE: Literature Review  
RECORD TYPE: Abstract  
LANGUAGE: English  
SUMMARY LANGUAGE: English

ABSTRACT: DNA vaccines were introduced less than a decade ago but have already been applied to a wide range of infectious and malignant diseases. Here we \*review\* the current understanding of the mechanisms underlying the activities of these new vaccines. We focus on recent strategies designed to enhance their function including the...

...transfected with 'self-replicating' vectors briefly produce large amounts of antigen before undergoing apoptotic death. This death is a likely result of requisite double-stranded (\*ds\*) \*RNA\* intermediates,

which also have been shown to super-activate DC. Thus, the enhanced immunogenicity of 'self-replicating' genetic vaccines may be a result of the...

DESCRIPTORS:

CHEMICALS & BIOCHEMICALS: ...\*vaccine\*; ...

...\*vaccine\*;

22/3,K/3 (Item 2 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2001 BIOSIS. All rts. reserv.

09497702 BIOSIS NO.: 199497506072

**African horse sickness virus structure.**

AUTHOR: Roy Polly(a); Mertens Peter P C; Casal Ignacio

AUTHOR ADDRESS: (a)Sch. Public Health, Univ. Alabama at Birmingham, 408  
Tidwell Hall, 720 South 20th Street, Birmin\*\*USA

JOURNAL: Comparative Immunology Microbiology and Infectious Diseases 17 (3-4):p243-273 1994

ISSN: 0147-9571

DOCUMENT TYPE: Literature Review

RECORD TYPE: Abstract

LANGUAGE: English

SUMMARY LANGUAGE: English; French

...ABSTRACT: VP3 and VP7, and three minor proteins, VP1, VP4 and VP6. Within the core is the virus genome. This genome consists of 10 double-stranded (\*ds\*) \*RNA\* segments of different sizes, three large, designated L1-L3, three medium, M4-M6, and four small, S7-S10. In addition to the seven structural proteins...

...S8 and S10) and the predicted amino acid sequences of the encoded gene products are also available, mainly representing one serotype, AHSV-4. In this \*review\* the properties of the AHSV genes and gene products are discussed. The sequence and hybridization analyses of the different AHSV dsRNA segments indicate that the...

...have been purified and used to raise antisera in rabbits. The VP2 antisera neutralize virus infections in vitro indicating the importance of this protein for \*vaccine\* development.

MISCELLANEOUS TERMS: ...\*VACCINE\* ANTIGEN POTENTIAL

22/3,K/4 (Item 1 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2001 Elsevier Science B.V. All rts. reserv.

02186400 EMBASE No: 1982103536

**A brief \*review\* of the development of diagnostic methods in systemic lupus erythematosus**

Wen-cheng Wang; Fang R.C.Y.; Shou-hwa Han

Sect. Clin. Immunol., Dept. Med., Veter. Gen. Hosp., Taipei Taiwan

Chinese Medical Journal (Taipei) ( CHIN. MED. J. TAIPEI ) (Taiwan) 1981, 28/5 (477-488)

CODEN: CIHCD

DOCUMENT TYPE: Journal

LANGUAGE: CHINESE SUMMARY LANGUAGE: ENGLISH

**A brief \*review\* of the development of diagnostic methods in systemic lupus erythematosus**

...the basis of immunological laboratory data which can be classified as seroimmunologic findings and immunopathologic findings. In seroimmunology, there which cannot fulfil for FANA, anti-\*ds\* \*DNA\*, LE cell preparation, anti-ENA, anti-Sm, complements, etc. In immunopathology, immunofluorescent

examination of renal and non-lesional skin biopsies is the main test. There

...name of SLE is ugly to Chinese patients. It is difficult to cure. A patient generally reacts with psychological shock to an SLE diagnosis. The \*treatment\* of SLE is usually carried out with immunosuppressive agents such as steroids over a long time. The complications from immunosuppressive \*treatment\* can cause grave consequences in the patient. Therefore, the diagnosis of SLE in patients should be made with great care, without mistakes or delays. The...

...ARA Criteria or the VGH Eight-Point Criteria, or a positive finding in one or more items in the following: FANA, LE clot test, anti-\*ds\* \*DNA\*, decreased C3 or C4, anti-Sm, LBT, and immunofluorescent examination of renal biopsy. Lastly, the possibilities of other different diagnoses are excluded.

?ds

Set	Items	Description
S1	2608	(DS (W) (RNA OR DNA OR OLIGONUCLEOTIDE OR POLYNUCLEOTIDE OR PLASMID))
S2	3	S1 AND (MHC (W) GENE)
S3	1	RD (unique items)
S4	120	S1 AND (TAP-1 OR TAP-2 OR PKR OR IFNBETA OR MAP OR JAK OR - STAT)
S5	0	S4 AND (ANITGEN (W) PRESENTATION)
S6	0	S4 AND (ANTIGEN (W) PRESENTATION)
S7	0	S4 AND (AUTOIMMUNE (W) DISEASE)
S8	0	S4 AND (AUTOIMMUNE)
S9	0	S4 AND (IMMUNE (W) RECOGNITION)
S10	0	S4 AND ((ABERRANT OR ENHANCED) (W) (EXPRESSION))
S11	0	S4 AND (THYROID OR THYROCYTE)
S12	4	S1 AND (ANTIGEN (W) PRESENTING (W) CELL?)
S13	2	RD (unique items)
S14	8	S1 AND (AUTOIMMUNE (W) RESPONSE)
S15	5	RD (unique items)
S16	5	S1 AND (ANTIGEN (W) PRESENTATION)
S17	3	RD (unique items)
S18	0	S1 AND (NON (W) SPECIFIC (W) SEQUENCE)
S19	355	S1 AND (VACCINE OR TREATMENT OR IMMUNOTHERAPY)
S20	203	RD (unique items)
S21	0	S20 AND (ENHANCED (W) IMMUNE (W) RESPONSE)
S22	4	S20 AND (REVIEW)

?s au=(Kohn, l?) or (kohn l?)

0 AU=KOHN, L?

0 KOHN L?

S23 0 AU=(KOHN, L?) OR (KOHN L?)

?s au=(kohn, leonard) or (kohn leonard)

0 AU=KOHN, LEONARD

0 KOHN LEONARD

S24 0 AU=(KOHN, LEONARD) OR (KOHN LEONARD)

?s au=(suzuki, k?) or (suzuki k?)

0 AU=SUZUKI, K?

3 SUZUKI K?

S25 3 AU=(SUZUKI, K?) OR (SUZUKI K?)

?rd

...completed examining records

S26 3 RD (unique items)

?t s26/3,k/all

26/3,K/1 (Item 1 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2000 Dialog Corporation. All rts. reserv.

09429229 98141341

Twenty five years of the "psychosine hypothesis": a personal perspective of its history and present status.

Suzuki K  
Neuroscience Center, Department of Neurology and Psychiatry, University  
of North Carolina School of Medicine, Chapel Hill 27599, USA.  
Neurochemical research (UNITED STATES) Mar 1998, 23 (3) p251-9, ISSN  
0364-3190 Journal Code: NX9  
Languages: ENGLISH  
Document type: BIOGRAPHY; HISTORICAL ARTICLE; JOURNAL ARTICLE; REVIEW;  
REVIEW, TUTORIAL

Named Person: \*Suzuki K\*

**26/3,K/2 (Item 2 from file: 155)**  
DIALOG(R)File 155:MEDLINE(R)  
(c) format only 2000 Dialog Corporation. All rts. reserv.

08184159 94293041

**Saul R. Korey Lecture. Molecular genetics of Tay-Sachs and related disorders: a personal account.**

Suzuki K  
Department of Neurology and Psychiatry, University of North Carolina  
School of Medicine, Chapel Hill 27599-7250.

Journal of neuropathology and experimental neurology (UNITED STATES)  
Jul 1994, 53 (4) p344-50, ISSN 0022-3069 Journal Code: JBR  
Contract/Grant No.: R01-NS-28997, NS, NINDS; R01-NS-24289, NS, NINDS;  
P30-HD-03110, HD, NICHD  
Languages: ENGLISH  
Document type: BIOGRAPHY; HISTORICAL ARTICLE; JOURNAL ARTICLE; REVIEW;  
REVIEW, TUTORIAL

Named Person: \*Suzuki K\*

**26/3,K/3 (Item 3 from file: 155)**  
DIALOG(R)File 155:MEDLINE(R)  
(c) format only 2000 Dialog Corporation. All rts. reserv.

01778830 68243818

**[Reminiscences of Professor Kiyoshi Suzuki]**

Yamagata K  
Kaibogaku zasshi (JAPAN) Aug 1 1967, 42 (4) p275-7, Journal Code:  
09W  
Languages: JAPANESE  
Document type: BIOGRAPHY; HISTORICAL ARTICLE; JOURNAL ARTICLE

Named Person: \*Suzuki K\*

?ds

Set	Items	Description
S1	2608	(DS (W) (RNA OR DNA OR OLIGONUCLEOTIDE OR POLYNUCLEOTIDE OR PLASMID))
S2	3	S1 AND (MHC (W) GENE)
S3	1	RD (unique items)
S4	120	S1 AND (TAP-1 OR TAP-2 OR PKR OR IFNBETA OR MAP OR JAK OR - STAT)
S5	0	S4 AND (ANTIGEN (W) PRESENTATION)
S6	0	S4 AND (ANTIGEN (W) PRESENTATION)
S7	0	S4 AND (AUTOIMMUNE (W) DISEASE)
S8	0	S4 AND (AUTOIMMUNE)
S9	0	S4 AND (IMMUNE (W) RECOGNITION)
S10	0	S4 AND ((ABERRANT OR ENHANCED) (W) (EXPRESSION))
S11	0	S4 AND (THYROID OR THYROCYTE)
S12	4	S1 AND (ANTIGEN (W) PRESENTING (W) CELL?)
S13	2	RD (unique items)
S14	8	S1 AND (AUTOIMMUNE (W) RESPONSE)
S15	5	RD (unique items)